New River submits NRP104 NDA

NRPH submitted an NDA to FDA for NRP104 to treat pediatric ADHD. NRPH hopes to launch NRP104 next year. The amphetamine prodrug is partnered with Shire (LSE:SHP; SHPGY). On Wednesday, NRPH rose $0.82 ...